A trial for the prevention of Alzheimer's disease for young people

The Washington University School of Medicine in St.

The new study, called "Primary Prevention Trial," will investigate gantenerumab, an experimental antibody against Alzheimer's disease being developed by Roche and Roche Group member Genentech.

"A lot of evidence suggests that the most effective way to slow or stop amyloid is to prevent its accumulation in the first place, but most drugs targeting this protein have been tested on people who already have at least some early symptoms, such as Memory loss-When the disease has progressed to a certain level, it is impossible to stop it by simply reducing amyloid," said Eric McDade, associate professor of neurology and lead researcher of the trial

This new trial involves families with rare genetic mutations that can cause Alzheimer's disease when they are young, usually at the age of 50, 40 or even 30

Preventing the earliest signs of disease may change the rules of the game in the field of Alzheimer's disease prevention.

Dr.

This trial will recruit people with rare early-onset Alzheimer’s disease, but the results will also further deepen our overall understanding of Alzheimer’s disease, which may benefit millions of people with the more common Alzheimer’s disease.

McDade and his colleagues are studying about 230 participants from families who carry a gene mutation that causes early-onset Alzheimer's disease

"This trial is the first, and it aims to intervene in young people with obvious neuropathology who are at a very high risk of developing debilitating symptoms of Alzheimer's dementia," said Luo Li, Ph.

This new trial is the second international Alzheimer's disease prevention trial led by Washington University School of Medicine

"The Cavalier Family DIAN-TU prevention trial is testing multiple drugs, including people who are expected to develop symptoms within 10 years," said Randall J.

The new test will take samples from the same group of families, with the purpose of determining whether targeting amyloid can prevent familial Alzheimer's disease

Fred Miller, Chief Operating Officer of the GHR Foundation and Alzheimer's Project Leader, said: "Thinking of this groundbreaking trial will provide valuable insights for the prevention of Alzheimer's.

Both trials were conducted in conjunction with the Dominant Alzheimer's Disease Network (DIAN)

Dr.
Maria C.
Carrillo, Chief Scientific Officer of the Alzheimer’s Association, said: “The Alzheimer’s Association has always been a long-term partner of DIAN.
We are particularly proud that we established and launched the trial in March 2012.
The unit provided initial funding
.
" "Electrograph is a milestone project that has greatly accelerated the discovery of Alzheimer's disease treatment and prevention strategies, and this innovative new prevention research is no exception
.
"

Without the support of many partners and the active participation of the DIAN family, this international effort to find a way to prevent Alzheimer's disease would be impossible
.

McDade said: "This is a big deal, and research like this is very expensive to carry out
.
" "We are grateful for the support from many sources that made this trial possible
.
We are also grateful to these families for their encouragement and willingness.
Take part in such an experiment
.
"